Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Celldex Therapeutics, Inc. (CLDX)

37.33 +0.55 (+1.50%)
As of 10:59:53 AM EDT. Market Open.
Trade CLDX on Coinbase
Chart Range Bar
Loading chart for CLDX
  • Previous Close 36.78
  • Open 36.95
  • Bid 31.56 x 100
  • Ask 42.66 x 100
  • Day's Range 36.17 - 37.54
  • 52 Week Range 19.72 - 39.16
  • Volume 166,608
  • Avg. Volume 993,452
  • Market Cap (intraday) 2.93B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) --
  • EPS (TTM) -4.27
  • Earnings Date (est.) Aug 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 57.53

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

www.celldex.com

198

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 7/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLDX
37.44%
S&P 500 (^GSPC)
9.60%

1-Year Return

CLDX
68.84%
S&P 500 (^GSPC)
20.48%

3-Year Return

CLDX
10.02%
S&P 500 (^GSPC)
68.59%

5-Year Return

CLDX
10.28%
S&P 500 (^GSPC)
72.38%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 15k
Earnings -78.69M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-80M
-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

38.00
57.53 Average
37.33 Current
90.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/15/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 42 -> 42

Statistics

View More

Valuation Measures

Annual
As of 7/1/2026
  • Market Cap

    2.89B

  • Enterprise Value

    2.44B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.83k

  • Price/Book (mrq)

    6.33

  • Enterprise Value/Revenue

    2.82k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.89%

  • Return on Equity (ttm)

    -48.94%

  • Revenue (ttm)

    865k

  • Net Income Avi to Common (ttm)

    -283.65M

  • Diluted EPS (ttm)

    -4.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    451.46M

  • Total Debt/Equity (mrq)

    0.42%

  • Levered Free Cash Flow (ttm)

    -126.27M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

37.33 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: